NITROGLYCERIN IN 5% DEXTROSE INJ.-100MCG/ML SOLUTION

מדינה: קנדה

שפה: אנגלית

מקור: Health Canada

מרכיב פעיל:

NITROGLYCERIN; DEXTROSE

זמין מ:

BAXTER CORPORATION

קוד ATC:

C01DA02

INN (שם בינלאומי):

GLYCERYL TRINITRATE

כמות:

10MG; 5G

טופס פרצבטיות:

SOLUTION

הרכב:

NITROGLYCERIN 10MG; DEXTROSE 5G

מסלול נתינה (של תרופות):

INTRAVENOUS

יחידות באריזה:

250ML

סוג מרשם:

Ethical

איזור תרפויטי:

NITRATES AND NITRITES

leaflet_short:

Active ingredient group (AIG) number: 0227179002; AHFS:

מצב אישור:

MARKETED

תאריך אישור:

1995-12-31

מאפייני מוצר

Page 1 of 17
PRODUCT MONOGRAPH
NITROGLYCERIN IN 5% DEXTROSE INJECTION
25 mg Nitroglycerin in 5% Dextrose Inj. 250mL
50 mg Nitroglycerin in 5% Dextrose Inj. 250mL
100 mg Nitroglycerin in 5% Dextrose Inj. 250mL
Professed Standard
VASODILATOR
Baxter Corporation
Revision Date: July 9, 2016
Mississauga, Ontario L5N 0C2
Submission Control No: 192761
Baxter is a registered trademark of Baxter International Inc.
Page 2 of 17
PRODUCT MONOGRAPH
NITROGLYCERIN IN 5% DEXTROSE INJECTION
25 mg Nitroglycerin in 5% Dextrose Inj. 250mL
50 mg Nitroglycerin in 5% Dextrose Inj. 250mL
100 mg Nitroglycerin in 5% Dextrose Inj. 250mL
Professed Standard
VASODILATOR
ACTIONS AND CLINICAL PHARMACOLOGY
The principal pharmacological action of nitroglycerin is relaxation of
vascular smooth muscle
and consequent dilation of peripheral arteries and veins, especially
the latter. Nitrates probably
act primarily by reducing oxygen demand rather than by increasing
myocardial oxygen supply.
Dilation of the veins promotes peripheral pooling of blood and
decreases venous return to the
heart, thereby reducing left ventricular end-diastolic pressure and
pulmonary capillary wedge
pressure (preload). Arteriolar relaxation reduces systemic vascular
resistance, systolic arterial
pressure, and mean arterial pressure (afterload). Dilation of the
coronary arteries also occurs.
The relative importance of preload reduction, afterload reduction, and
coronary dilation remains
undefined.
Blinded, placebo-controlled trials of intravenous nitroglycerin have
not been reported, but
multiple investigators have reported open-label studies, and there are
scattered reports of
studies
in
which
intravenous
nitroglycerin
was
tested
in
blinded
fashion
against
sodium
nitroprusside.
In each of these studies, therapeutic doses of intravenous
nitroglycerin were found to reduce
systolic and diastolic arterial blood pressure. The heart rate was
usually increased, presumably
as a reflexive response to the fall in blood pressure. Coronary
perfusion pressure was usually,
but not always,